CN108066339B - A kind of pharmaceutical composition of Parecoxib Sodium - Google Patents
A kind of pharmaceutical composition of Parecoxib Sodium Download PDFInfo
- Publication number
- CN108066339B CN108066339B CN201810137367.6A CN201810137367A CN108066339B CN 108066339 B CN108066339 B CN 108066339B CN 201810137367 A CN201810137367 A CN 201810137367A CN 108066339 B CN108066339 B CN 108066339B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parecoxib sodium
- sodium
- analgesic
- ginkgolides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of pharmaceutical compositions of Parecoxib Sodium, belong to field of medicaments.SC 69124 increases during analgesia as dosage and exposure duration increase, and the raising that then will appear liver transaminases is used for a long time, to influence the clinical application range of drug.In order to overcome the technical deficiency of erious adverse reaction during analgesia therapy in the prior art; the present invention provides a kind of for analgesic pharmaceutical composition; it is using Parecoxib Sodium and ginkgolides as active pharmaceutical ingredient; when the pharmaceutical composition is used for analgesia therapy; two kinds of active components have significant synergistic effect in ease pain; and can significantly reduce the adverse reaction of drug, significant protective effect especially is embodied to liver, therefore be suitable for developing into clinical treatment drug.
Description
Technical field
The present invention relates to a kind of pharmaceutical compositions of Parecoxib Sodium, belong to field of medicaments.
Background technique
Parecoxib Sodium, chemical name: N- [[4- (5- methyl -3- phenyl -4- isoxazolyl) phenyl] sulfonyl] propionyl
Amine sodium salt.Parecoxib Sodium is -2 acceptor inhibitor of injection-type selective COX-2, is the inactive precursor drug of Valdecoxib, town
Bitterly rapid-action, half-life short can not only inhibit periphery and maincenter COX-2 receptor active, may also suppress the quick of periphery and maincenter
Change, generates good analgesic effect.
SC 69124 declares listing in European Union in March, 2002 by Pfizer, and trade name " special resistance to ", which is to cut down ground former times
The pro-drug of cloth.In May, 2008, Pfizer's injection Parecoxib Sodium list in China, and dosage form is powder-injection, and specification has two
Kind, respectively 20mg, 40mg.
From the point of view of sample hospital market, the enterprise for entering sample hospital data statistics for 2015 only has import enterprise 1, is
Pfizer subordinate's Pharmacia (Pharmacia) company.Domestic SC 69124 medication market scale is from 18,270,000 yuan of 2009 increasings
2.1 hundred million yuan in 2015 are grown to, 2009-2015 annual compound growth rate is 50.1%, which has kept higher since listing
Growth rate, but the product market in 2015 starts to slow down.
The recommended dose of Parecoxib Sodium is 40mg, is injected intravenously (IV) or intramuscular injection (IM) administration, then optionally
20mg or 40mg is given at interval for 6-12 hours, and daily accumulated dose is no more than 80mg.Rapid intravenous bolus injection can be directly carried out, or is passed through
Existing venous channel administration.Intramuscular injection should select deep part muscle slowly to inject.
It is limited using clinical experience of this drug more than three days at present.Opium kind analgesics can answer simultaneously with SC 69124
With in all clinical assessments, SC 69124 is fixed interval administration, and opioid drug is then to be administered on demand.By
Mixedly appear precipitating in the solution in SC 69124 and other medicines, no matter therefore in dissolution or injection process, pa auspicious former times
Cloth is forbidden to mix with other medicines.As SC 69124 and other medicines use same venous channel, the injection of SC 69124 solution
Front and back must sufficiently rinse venous channel using compatible solution.Occur additionally, due to the cardiovascular event of Selective COX-2 inhibitor
Risk increases as dosage and exposure duration increase, and therefore, should use most Low doses and minimum daily effective dose as far as possible.
Therefore, the compatibility and its clinical application risk of SC 69124 and other drugs are to expand SC 69124 clinical application range
Key factor.
" SC 69124 is analyzed in the Meta of backbone Postoperative Analgesia After curative effect " collects related SC 69124 in backbone Postoperative Analgesia After
Randomized controlled trial (RCT).By two researchers according to being included in and exclusion criteria screening document, extraction data and evaluation quality
Afterwards, Meta analysis is carried out using RevMan5.0 software.As a result: being included in 12 RCT altogether, totally 636 patients.Meta analyzes result
Display: postoperative 2,6,12,24,48h, SC 69124 with placebo compared with, VAS scoring have apparent heterogeneity (P <
0.05), difference on effect is statistically significant.Conclusion: SC 69124 can achieve satisfied analgesic effect in backbone Postoperative Analgesia After,
It can be used as the postoperative Conventional analgesics treatment of backbone.
Summary of the invention
SC 69124 increases during analgesia as dosage and exposure duration increase, and long-time service then will appear liver
The raising of transaminase, to influence the clinical application range of drug.It is bad during analgesia therapy in the prior art in order to overcome
Big technical deficiency is reacted, the present invention provides one kind for analgesic pharmaceutical composition, with Parecoxib Sodium and ginkgolides
For active pharmaceutical ingredient, when the pharmaceutical composition is used for analgesia therapy, two kinds of active components have significant in ease pain
Synergistic effect, and can significantly reduce the adverse reaction of drug, significant protective effect especially embodied to liver, therefore be suitable for
Develop into clinical treatment drug.
An object of the present invention be to provide it is a kind of for analgesic pharmaceutical composition, the composition with Parecoxib Sodium with
Ginkgolides is active constituent, is formed with pharmaceutically acceptable auxiliary material combination.
Test examples of the present invention show two kinds it is medication combined for easing pain, the pharmaceutical composition is controlled for easing pain
When treatment, two kinds of active component combinations not only have significant synergistic effect in ease pain, and can significantly reduce SC 69124
Adverse reaction, especially to preventing liver transaminases raising embody significant effect.
The weight ratio of Parecoxib Sodium and ginkgolides is 1:0.05-1 in the pharmaceutical composition.Further preferably
1:0.5。
The second object of the present invention is to providing the pharmaceutical preparation comprising aforementioned pharmaceutical compositions.Aforementioned pharmaceutical compositions of the present invention
When pharmaceutical composition is used for clinical treatment, preferably freeze drying powder injection.Specification is 3mL/ branch in the freeze drying powder injection, wherein excellent
The content for being selected as Parecoxib Sodium in per unit preparation is 5mg-10mg, and the content of ginkgolides is 0.5-5mg.
Prescription and content composition of the applicant also to the freeze drying powder injection comprising above-mentioned composition are screened, and drug is worked as
When composition is prepared into freeze drying powder injection, pharmaceutically acceptable auxiliary material can be mannitol, water for injection, sodium chloride, citric acid
Sodium, dextran, disodium hydrogen phosphate, sodium dihydrogen phosphate etc..Freeze drying powder injection described above can also be according to the property of drug
Suitable additives are added, such as osmotic pressure regulator, pH adjusting agent, solubilizer, antioxidant, bacteriostatic agent, emulsifier, suspending agent
Deng.It has been found that the stability of pharmaceutical preparation is preferable when the freeze drying powder injection of pharmaceutical composition composition is as follows.
The present invention also provides a kind of preparation methods of above-mentioned freeze drying powder injection comprising following steps: distinguishing by recipe quantity
Weigh Parecoxib Sodium, ginkgolides, mannitol.Mannitol is added in appropriate water for injection, stirring and dissolving and with 0.1%
(w/v) activated carbon adsorption, 0.45 μm of filter or filter membrane pre-filtering are added Parecoxib Sodium stirring and dissolving and are adjusted with sodium hydroxide
PH value is to 7.0-8.5, constant volume after 0.45 μm of filter or filter membrane pre-filtering, 0.45 μm and 0.22 μm of filter or filter membrane aseptic filtration
Afterwards, filling, half tamponade is freeze-dried to obtain the freeze drying powder injection of the present composition.
Third object of the present invention is that a kind of medical usage of aforementioned pharmaceutical compositions, i.e., the described drug is claimed
Composition is preparing the purposes in analgesic.Pharmaceutical composition of the present invention can reduce liver caused by chemotherapeutics and turn ammonia
Enzyme increases, and has significant synergistic effect in ease pain, therefore can be used for clinical analgesia.For treating the disease
When, the preferential freeze drying powder injection described above using the present invention.
When pharmaceutical composition of the present invention is treated for chronic obstructive pulmonary disease, there is following technical advantage:
1) two kinds in pharmaceutical composition of the present invention are medication combined for easing pain, and not only have significant association in ease pain
Same-action, and chemotherapeutics can be significantly reduced after drug combination for the detrimental effect of liver.
2) it is damaged when existing clinical treatment drug SC 69124 has biggish liver damage effect, especially long-term administration
Evil more very, drastically influences the therapeutic effect of drug.Plus it can be with ginkgolides on the basis of using analgesic SC 69124
The adverse reaction for significantly reducing drug, so that the quality of life of patient is obviously improved.
3) present composition can make patient medication more convenient after being prepared into freeze drying powder injection, dosage precise control,
And the daily medication of pharmaceutical composition of the present invention is primary, so that the compliance of patient greatly improves, medical expense is decreased obviously.
Specific embodiment
The present invention is further illustrated below by way of specific embodiment, but those skilled in the art should be able to know, the implementation
Example does not limit the scope of protection of the present invention in any way.
The freeze drying powder injection of the pharmaceutical composition of the present invention of embodiment 1
Composition:
Preparation process: Parecoxib Sodium, ginkgolides, mannitol are weighed respectively by recipe quantity.Mannitol is added to suitable
Measure water for injection in, stirring and dissolving and use 0.1% (w/v) activated carbon adsorption, 0.45 μm of filter or filter membrane pre-filtering, addition pa it is auspicious
Former times cloth sodium stirring and dissolving simultaneously adjusts pH value to 7.0-8.5 with sodium hydroxide, constant volume after 0.45 μm of filter or filter membrane pre-filtering, and 0.45
μm and 0.22 μm of filter or filter membrane aseptic filtration after, filling, half tamponade is freeze-dried to obtain the jelly of the present composition
Dry powder injection.
The freeze drying powder injection of the pharmaceutical composition of the present invention of embodiment 2
Composition:
Preparation method is in addition to prescription is different, other same embodiment of the present invention 1.
The freeze drying powder injection of the pharmaceutical composition of the present invention of embodiment 3
Composition:
Preparation method is in addition to prescription is different, other same embodiment of the present invention 1.
The freeze drying powder injection of the pharmaceutical composition of the present invention of embodiment 4
Composition:
Preparation method is in addition to prescription is different, other same embodiment of the present invention 1.
The freeze drying powder injection of the pharmaceutical composition of the present invention of embodiment 5
Composition:
Preparation method is in addition to prescription is different, other same embodiment of the present invention 1.
The investigation of the medicinal composition freezing-dried powder injection of the present invention of embodiment 6 is tested
1. trial-manufacture of sample
By formulation and technology pilot sample four batches of 1-5 of the embodiment of the present invention, lot number is respectively as follows: 170506 (4146),
170508 (4220), 170510 (4301), 170512 (4187).Through examining four batches of samples to meet the requirements.
2. the project of investigation
Freeze-dried powder study on the stability under the test of 2.1 strong illuminations and hot test
Sample is removed into outer packing, (lot number is the medicinal composition freezing-dried powder injection of the present invention for taking by full inspection qualification
170506) it is respectively placed under strong illumination (4500 ± 500Lx), high temperature (60 DEG C) and places 10 days, taken respectively in the 5th day and 10 days
Sample, and compareed with 0 day with batch sample data, it the results are shown in Table 1, table 2.Wherein the content in following experiments is two kinds of active components
Total content calculates.
High temperature (60 DEG C) test result of the medicinal composition freezing-dried powder injection of the present invention of table 1
Find out from result above, this product is removing outer packing, places 10 days under 60 DEG C of hot conditions, appearance character, pH
Value, related substance and content have no significant change.
Illumination (4500 ± 500Lx) test result of the medicinal composition freezing-dried powder injection of the present invention of table 2
Find out from result above, this product is removing outer packing, the related substance under the conditions of strong illumination (4500 ± 500Lx)
Content slightly increases, but still within prescribed limit.Show freeze-dried powder by illumination and high temperature factors influencing test result
Injection sample is basicly stable to heat, light, illustrates this product using general packaging, shading storage according to the above experimental result.
Freeze-dried powder stability test under 2.2 high humidity environments
Medicinal composition freezing-dried powder injection of the present invention (lot number 170506) Jing Guo full inspection qualification is respectively placed in 25 DEG C
(the KNO containing saturation in the environment of relative humidity 90% ± 5%3In the drier of solution), it places 10 days, respectively at the 5th day and the
10 days sample, detected, investigate its appearance character, pH value, content, in relation to substance, moisture in terms of variation, the results are shown in Table 3.
The accelerated test result of the medicinal composition freezing-dried powder injection of the present invention of table 3
Test result shows that compared with before test, the pH value of this freeze drying powder injection is basicly stable, changes in normal range (NR)
It is interior, it is basicly stable in relation to substance and active constituent content.
2.3 long term test
At room temperature by the medicinal composition freezing-dried powder injection of the present invention (lot number 170506) Jing Guo full inspection qualification,
Every bottle of 0.9% sodium chloride injection 3ml of addition makes it dissolve, and is uniformly mixed, places naturally under room temperature (25 DEG C), in 0,2,4,
6, the content of 8 hours sample detection solution, in relation to substance and pH value, carry out stability of solution after the redissolution of preparation and investigate test to grind
Study carefully.It the results are shown in Table 4.
The long-term test results of the medicinal composition freezing-dried powder injection of the present invention of table 4
Test result shows that compared with before test, the pH value after the redissolution of this freeze drying powder injection in 0-8 hours is basicly stable,
Variation is in the normal range, basicly stable in relation to substance and active constituent content.
3. conclusion (of pressure testing)
It is tested and is tied in the above influence factor by medicinal composition freezing-dried powder injection of the present invention prepared by preparation process of the present invention
Show that pH is basically stable at normal range (NR) under conditions of exposure experiments to light, hot test, high humidity test, redissolution test in fruit
Interior variation, drug content variation are stablized, and related Substances variation has raising, but still within the scope of defined.Wherein according to
The freeze drying powder injection that the embodiment of the present invention 1 is prepared is the most stable in terms of the variation of related substance and changes of contents, is this hair
Bright optimal embodiment.
The influence of mouse writhing number caused by the pharmaceutical composition Dichlorodiphenyl Acetate of the present invention of embodiment 7
1. animal packet and administration
Male ICR mouse 70, (20 ± 2) g, 7 groups are randomly divided by weight, every group 10, specific grouping situation is as follows:
2. experimental method and data processing
Mouse peritoneal injects acetic acid, causes abdominal cavity large area and more lasting pain stimulation, and mouse is caused to generate torsion
Precursor reactant.After each dosage group administration 1h, 0.7% acetic acid normal saline solution 0.1ml/10g is injected intraperitoneally, record injects acetic acid certainly
The writhing response number that every mouse occurs in 20min after induced pain, calculates the inhibitory rate of each administration group.
Inhibitory rate=[(control group writhing number-medicine group writhing number)/control group writhing number] × 100%
Experimental data withIt indicates, variance analysis is carried out using SPSS15.0 software.
3. experimental result
Experimental result is shown in Table 1
The influence of mouse writhing number caused by the pharmaceutical composition Dichlorodiphenyl Acetate of the present invention of table 1
Compared with model group,*P < 0.01；Compared with ginkgolides group,&&P < 0.01；
Compared with SC 69124 group, P < 0.01；Compared with high group of SC 69124,##P < 0.01.
Experimental result as shown in Table 1 is it is found that ginkgolides and SC 69124 are inhibiting acetic acid in each composition treatment group
There is apparent synergistic effect, inhibiting rate is not only significantly better than two kinds of drug given alones in terms of caused mouse writhing number
Group, the adduction of better than two kinds Drug inhibition rates, the analgesic effect of pharmaceutical composition of the present invention are also significantly better than existing antalgesic
Object SC 69124.It is specific as follows:
(1) compared with model group, each treatment group significantly inhibits work to writhing mouse writhing number caused by mouse acetic acid
With.
(2) compared with ginkgolides, SC 69124 independent medication, pharmaceutical composition group of the present invention has writhing inhibiting effect
Extremely significant sex differernce (P < 0.01), two medicines of display, which share, has synergistic effect, and two medicines share and reaching the same of equivalent effect
When, each single pharmaceutical quantities can be significantly reduced, and then reduce the generation of adverse reaction.
(3) compared with SC 69124 group, pharmaceutical composition group of the present invention to writhing inhibiting effect have extremely significant sex differernce (P <
0.01), the pharmaceutical composition analgesic effect is more preferable.
The influence that the pharmaceutical composition of the present invention of embodiment 8 reacts mouse hot-plate induced pain
1. animal packet and administration
Female ICR mice (20 ± 2) g is set on 55 ± 0.5 DEG C of intelligent hot-plate instrument, record mouse vola contacts hot plate
It is pain indicator to the incubation period (s) for occurring licking metapedes reaction, rejects the mouse of response latency < 5s or > 30s or jump.
Qualified mice of 70 response latencies in 10~30s is chosen, is randomly divided into 7 groups according to the preceding threshold of pain of medicine and weight, by as follows
Administration:
2. experimental method and data processing
Continuous gavage is administered 5 days, measures the threshold of pain 1 of each administration group mouse when 30,60,90,120min respectively after administration
Secondary, pain threshold is more than that 60s person is calculated with 60s.
Data withIt indicates, variance analysis is carried out using SPSS15.0 software.
3. experimental result
Experimental result is shown in Table 2
The influence that the pharmaceutical composition of the present invention of table 2 reacts mouse hot-plate induced pain
Compared with model group,*P < 0.05,*P < 0.01；Compared with ginkgolides group,&&P < 0.01；
Compared with SC 69124 group,#P < 0.05.
By 2 experimental result of table it is found that each administration group can improve the effect of the threshold of pain of mouse compared with model group, wherein silver
Apricot lactone and SC 69124 have significant synergistic effect in terms of improving the mouse threshold of pain, and the threshold of pain of composition A, B, C group is improved
Effect is better than the adduction that two kinds of drugs are used alone, and threshold of pain improvement effect is close with SC 69124, and wherein composition C group and pa are auspicious
Former times cloth group, which is compared, has significant difference.It is specific as follows:
(1) compared with model group, each treatment group significantly inhibits effect to hot plate induced pain mice pain.
(2) compared with ginkgolides, SC 69124 independent medication, pharmaceutical composition group of the present invention inhibits to make to hot-plate model
With having extremely significant sex differernce (P < 0.01), two medicines of display, which share, has synergistic effect, and two medicines are shared and be can be significantly reduced respectively
Single pharmaceutical quantities, and then reduce the generation of adverse reaction.
(3) compared with SC 69124 group, pharmaceutical composition group of the present invention has significant difference to hot plate induced pain inhibiting effect
(P < 0.05), the pharmaceutical composition are more preferable to the analgesic effect of hot plate induced pain.
Influence of 3 pharmaceutical composition of table to serum transaminase ALT and AST content
| Group | n | ALT(U/L) | AST(U/L) |
| Normal group | 20 | 66.21±7.13 | 78.25±7.96 |
| Model group | 20 | 536.74±22.36** | 658.65±35.19** |
| High group of SC 69124 | 20 | 732.36±242.83*** | 1052.68±35.62*** |
| High group of ginkgolides | 20 | 498.36±34.16 | 550.49±32.16 |
| Composition A group | 20 | 619.18±25.16▲ | 752.16±16.15▲ |
| Composition B group | 20 | 567.34±24.39▲▲ | 685.32±26.14▲▲ |
| Composition C group | 20 | 389.62±11.07▲▲ | 521.21±32.15▲▲ |
Compared with normal group,**P < 0.01,***P < 0.01；Compared with model group,#P < 0.05,##P < 0.01；
Compared with SC 69124 group,▲P < 0.05,▲▲P < 0.01；
As can be seen from the above table, ALT the and AST content of model group has significant difference, pa auspicious former times compared with normal group
ALT the and AST content of cloth group is more tight to the hepar damnification of rat after medication compared to showing with significant difference with normal group
Weight.After being combined ginkgolides, the transaminase of pharmaceutical composition each group has relative to SC 69124 group to be remarkably decreased, this shows this
Invention pharmaceutical composition has good liver protection.
Although above the present invention is described in detail with a general description of the specific embodiments,
On the basis of the present invention, it can be modified or is improved, this will be apparent to those skilled in the art, because
This, these modifications or improvements, belong to the scope of protection of the invention without departing from theon the basis of the spirit of the present invention.
Claims (7)
1. a kind of pharmaceutical composition for analgesic Parecoxib Sodium, which is characterized in that described pharmaceutical composition activity at
Divide and be made of Parecoxib Sodium and ginkgolides, the weight ratio of Parecoxib Sodium and ginkgolides is 1 in described pharmaceutical composition:
0.05-1。
2. being used for the pharmaceutical composition of analgesic Parecoxib Sodium as described in claim 1, which is characterized in that the medicine group
Closing the weight ratio of Parecoxib Sodium and ginkgolides in object is 1:0.5.
3. being used for the pharmaceutical composition of analgesic Parecoxib Sodium as described in claim 1, which is characterized in that include the medicine
The pharmaceutical preparation of compositions is freeze drying powder injection.
4. being used for the pharmaceutical composition of analgesic Parecoxib Sodium as claimed in claim 3, which is characterized in that the medicine group
The content for closing Parecoxib Sodium in per unit preparation in the freeze drying powder injection of object is 5mg-10mg, and the content of ginkgolides is
0.5-5mg。
5. being used for the pharmaceutical composition of analgesic Parecoxib Sodium as claimed in claim 3, which is characterized in that the medicine group
Close object freeze drying powder injection in pharmaceutically acceptable auxiliary material be mannitol, water for injection, sodium chloride, sodium citrate, dextran,
One of disodium hydrogen phosphate, sodium dihydrogen phosphate are a variety of.
6. being used for the pharmaceutical composition of analgesic Parecoxib Sodium as claimed in claim 3, which is characterized in that the medicine group
It closes and is prepared in 1000 preparation units of the freeze drying powder injection of object by following component:
Water for injection adds to 3000mL.
7. being used for the pharmaceutical composition of analgesic Parecoxib Sodium as claimed in claim 3, which is characterized in that the drug
The preparation method of the freeze drying powder injection of composition includes the following steps: to weigh Parecoxib Sodium, ginkgolides respectively by recipe quantity
And auxiliary material, auxiliary material is added in appropriate water for injection, stirring and dissolving and with 0.1% (w/v) activated carbon adsorption, 0.45 μm of filter
Or filter membrane pre-filtering, Parecoxib Sodium stirring and dissolving is added and adjusts pH value to 7.0-8.5 with sodium hydroxide, 0.45 μm of filter or
Constant volume after filter membrane pre-filtering, after 0.45 μm and 0.22 μm of filter or filter membrane aseptic filtration, filling, half tamponade, freeze-drying is
Obtain the freeze drying powder injection of described pharmaceutical composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810137367.6A CN108066339B (en) | 2018-02-10 | 2018-02-10 | A kind of pharmaceutical composition of Parecoxib Sodium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810137367.6A CN108066339B (en) | 2018-02-10 | 2018-02-10 | A kind of pharmaceutical composition of Parecoxib Sodium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108066339A CN108066339A (en) | 2018-05-25 |
| CN108066339B true CN108066339B (en) | 2018-12-14 |
Family
ID=62155101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810137367.6A Active CN108066339B (en) | 2018-02-10 | 2018-02-10 | A kind of pharmaceutical composition of Parecoxib Sodium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108066339B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3132227A1 (en) * | 2019-03-01 | 2020-09-10 | Eurofarma Laboratorios S.A. | Non-steroid anti-inflammatory pharmaceutical composition |
| CN112409283A (en) * | 2020-11-24 | 2021-02-26 | 苏州璞正医药有限公司 | Parecoxib derivative and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009514851A (en) * | 2005-11-08 | 2009-04-09 | ランバクシー ラボラトリーズ リミテッド | (3R, 5R) -7- [2- (4-Fluorophenyl) -5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino) carbonyl] -pyrrol-1-yl] -3,5 -Preparation of dihydroxy-heptanoic acid hemi-calcium salt |
| CN102068426B (en) * | 2009-11-24 | 2013-01-02 | 秦引林 | New application of Ginkgolide B derivative in medicament preparation |
| CN102512383A (en) * | 2011-12-25 | 2012-06-27 | 天津市嵩锐医药科技有限公司 | Parecoxib sodium pharmaceutical composition for injection |
-
2018
- 2018-02-10 CN CN201810137367.6A patent/CN108066339B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108066339A (en) | 2018-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kleijnen et al. | Mistletoe treatment for cancer review of controlled trials in humans | |
| CN108066339B (en) | A kind of pharmaceutical composition of Parecoxib Sodium | |
| KR20070054222A (en) | Medicine having analgesic effects | |
| CN108057018A (en) | Colchicin topical composition and preparation method thereof | |
| EP2862575A1 (en) | Application of piceatannol-3'-o-b-d-glucopyranoside in preparation of medicaments for improving microcirculation block | |
| CN102657602B (en) | 3,5-dyhydroxyl-4-isopropyl diphenylethene chitosan gel and preparation method thereof | |
| CN103816542A (en) | A pharmaceutical composition containing an analgesic and fospropofol disodium | |
| CN107519136A (en) | A kind of Choline Chloride Succinate lyophilized formulations and preparation method thereof | |
| CN104546822B (en) | The medical usage of epimedium aglucone | |
| CN106667924A (en) | Stable S-(-)-ornidazol disodium phosphate freeze-dried preparation and preparation method thereof | |
| Williams et al. | Prevention of central nervous system toxicity of the antitumor antibiotic acivicin by concomitant infusion of an amino acid mixture | |
| CN104922677B (en) | A kind of pharmaceutical composition of hydrochloric stephanine is preparing the application in treating leukopenic drug | |
| WO2022097764A1 (en) | Pharmaceutical composition comprising pregabalin and tianeptine for treating neuropathic pain | |
| CN104546697B (en) | A kind of Dexibuprofen injection pharmaceutical composition and preparation method thereof | |
| CN100548306C (en) | A kind of injection and preparation technology thereof who treats eperythrozoonosis of domestic animal | |
| CN114272259A (en) | Fluorouracil injection and preparation method thereof | |
| CN106177962A (en) | Pharmaceutical composition containing Sarpogrelate is for treating or prevent the purposes of fatty liver, hepatic fibrosis and/or hepatic injury | |
| CN103083338A (en) | Synergetic compound analgin injection and preparation method thereof | |
| Manmuan et al. | Evaluation of standardized extract of Centella Asiatica on cell viability and repressive cancer migration in metastatic colorectal cancer cells in vitro | |
| WO2019242764A1 (en) | Application of glycosides in the preparation of drugs for preventing and treating diabetes complications | |
| CN100377712C (en) | Cucurbitacin lipsome preparation method and formulation | |
| CN101181440B (en) | Chinese medicine composition for curing hemopathy as well as preparation method and usage thereof | |
| CN110898042B (en) | Salbutamol sulfate solution for inhalation and preparation method thereof | |
| CN105997899A (en) | Asarone drug composition for injection or inhalation | |
| CN102091326B (en) | Transdermal medicament delivery preparation for treating hemorrhoid diseases caused by expansion or varix of anal subcutaneous veniplex and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |